| 09 Mar 2008 |
|
Globalpharma unveils its latest production at DUPHAT 2008
- Text size
Dubai - UAE March 9, 2008: GlobalpharmaGlobalpharma
, a subsidiary of Dubai Investments Industries, the industry arm of Dubai Investments PJSC and the first pharmaceutical manufacturing company in Dubai that adheres to international quality standards, is to reinforce its commitment as a premier regional healthcare provider as it participates in DUPHAT 2008 - Dubai International Pharmaceuticals & Technologies Conference & Exhibition which will take place between March 10 - 12 at the Dubai International Exhibition Center."Recent reports have revealed that the Middle East is a rapidly growing market for medical products and services. As more and more expatriates move to the Gulf and Arab region, the need for first-rate healthcare has also exponentially grown. The UAE tops the list as the Middle Eastern country with the highest annual per capita consumption of medicines", said Syed Jamil Akhtar, General Manager, GlobalpharmaGlobalpharma.
"In light of this and in view of other challenges facing the pharmaceutical industry, DUPHAT is truly appreciated industry-wide as a leading unique regional platform that fosters mutual interaction between professionals, students and academics of pharmaceutical science. We are proud to be part of DUPHAT 2008."
The three-day exhibition will witness GlobalpharmaGlobalpharma unveil its latest products and present an overview on breakthrough products that are in the final stages of development and to be launched shortly. It will also showcase its advanced international standard manufacturing processes and present to attendees, major findings from its pharma and medical research undertaken over the last year.
"As part of its mission to be a premier healthcare company that constantly strives to deliver high-quality medicines that improve the quality of human life, GlobalpharmaGlobalpharma
is in the process of negotiating and finalizing deals with certain prominent research institutes and leading research-based pharmaceutical companies to acquire products with added value in the area of cardiovascular disease, aids, diabetes and oncology", Akhtar added."GlobalpharmaGlobalpharma has achieved an excellent 70 percent growth in 2007 and we look forward to emulating similar success in the coming year. While the task is challenging, we are confident that we will shortly be entering new markets such as South Africa and certain countries in the CIS region, launching between 7 - 8 new products in each major market."
"We are also working towards obtaining approvals from international authorities such as the Medicines and Healthcare products Regulatory Agency, UK and the Food and Drug Authority (FDA), USA in coming months.
Established in 1998, GlobalpharmaGlobalpharma manufactures and markets its own pharmaceutical products including antibiotics, cardiovascular, anti-ulcerants, analgesic NSAIDs, food supplements, vitamins, anti-diabetics, respiratory products in more than 20 countries of GCC, Middle East, Africa and Far east, in addition to marketing in license products from some other multinational pharmaceutical companies.
-Ends-
MEDIA CONTACTS:
Sue-Ellen Lazrado Headline Public Relations
Tel: 9714 - 2289655 Ext 120
Fax: 9714 - 2282125
Email: sue@headlinepr.com
© Press Release 2008
Zawya is a distributor (and not a publisher) of content supplied by third parties and subscribers. Any opinions, advice, statements, services, offers, or other information or content expressed or made available by those third parties, including information providers, subscribers or other users of the Service, are those of the respective author(s) or distributor(s) and not of the Company. The Company neither endorses nor is responsible for the accuracy or reliability of any opinion, advice or statement made on the Service by anyone other than authorized Service employee spokespersons while acting in their official capacities. The Company is not responsible for any infringement of intellectual property rights or breach of any applicable law or regulation, including regulation in relation to financial services or the distribution of financial products, defamation, data protection, telecommunications (including regulations relating to excessive use, spamming or other abusive activities) or obscene, offensive or illegal content). Under no circumstances will the Company be liable for any loss or damage caused by a member's reliance on information obtained through the Service. It is the responsibility of member to evaluate the accuracy, completeness or usefulness of any information, opinion, advice or other content available through the Service. Please seek the advice of professionals, as appropriate, regarding the evaluation of any specific information, opinion, advice or other content.
Read the full Member Agreement
http://www.zawya.com/legal/NewsLetter.cfm?name=disclaimer
Post a Comment
1.1 Contain any material which is libelous or defamatory of any person, is obscene, offensive, hateful or inflammatory or causes damage to the reputation of any person or organisation.
1.2 Promote sexually explicit material, violence, discrimination based on race, sex, religion, nationality, disability, sexual orientation or age or any illegal activity.
1.3 Be made in breach of any legal duty owed to a third party, such as a contractual duty or a duty of confidence.
1.4 Be threatening, abuse or invade another's privacy, or cause annoyance, inconvenience or needless anxiety.
1.5 Be used to impersonate any person, to misrepresent your identity or affiliation with any person, or be likely to deceive any person.
1.6 Give the impression that they represent Zawya.
1.7 Advocate, promote or assist any unlawful act such as (by way of example only) copyright infringement or computer misuse.